VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GRDNGuardian Pharmacy Services, Inc.
$46.94$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. GRDN
  4. Financial Ratios

Guardian Pharmacy Services, Inc. (GRDN) Financial Ratios

Latest Ratios: P/E Ratio 40.1x · EV/EBITDA 23.8x · ROE 26.8%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

GRDN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$3.0B$1.9B$1.3B——————
Enterprise Value$2.9B$1.9B$1.3B——————
P/E Ratio →40.1338.58———————
P/S Ratio2.041.311.02——————
P/B Ratio13.638.748.38——————
P/FCF30.9123.6030.20——————
P/OCF29.6418.9921.67——————

P/E links to full P/E history page with 30-year chart

GRDN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—1.301.04——————
EV / EBITDA23.8516.86———————
EV / EBIT33.1125.32———————
EV / FCF—23.2530.82——————

GRDN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin19.5%19.5%19.9%19.9%20.4%20.4%20.0%20.5%20.5%
Operating Margin6.1%6.1%-5.1%3.9%5.7%3.8%4.4%4.9%4.3%
Net Profit Margin3.4%3.4%-7.1%2.3%3.9%2.1%2.7%3.1%2.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE26.8%26.8%-83.2%35.2%54.8%27.1%42.1%45.4%21.6%
ROA13.4%13.4%-29.5%9.1%14.4%7.2%9.6%11.5%8.1%
ROIC36.6%36.6%-31.1%23.0%33.7%21.3%23.6%26.4%—
ROCE41.5%41.5%-40.6%29.5%38.7%23.6%27.0%30.6%22.3%

GRDN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.170.170.201.160.831.030.882.060.64
Debt / EBITDA0.330.33—1.170.921.181.191.141.12
Net Debt / Equity—-0.130.171.140.820.750.782.050.61
Net Debt / EBITDA-0.26-0.26—1.160.910.861.061.141.06
Debt / FCF—-0.350.611.221.960.811.181.371.23
Interest Coverage111.41111.41-19.2814.1926.7818.3014.7614.9413.25

Net cash position: cash ($66M) exceeds total debt ($37M)

GRDN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio1.381.381.050.941.071.001.091.001.24
Quick Ratio1.111.110.770.670.700.710.720.660.82
Cash Ratio0.410.410.030.010.010.130.070.000.03
Asset Turnover—3.513.833.863.553.363.383.553.30
Inventory Turnover26.9126.9124.2722.8117.4519.0618.4517.9317.33
Days Sales Outstanding—25.6028.8726.9627.2425.4622.7028.3428.97

GRDN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield——2.8%——————
Payout Ratio———160.7%87.0%106.4%54.2%114.6%156.1%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield2.5%2.6%———————
FCF Yield3.2%4.2%3.3%——————
Buyback Yield1.0%1.5%4.4%——————
Total Shareholder Yield1.0%1.5%7.2%——————
Shares Outstanding—$63M$62M$61M$61M$61M$61M$61M$61M

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetFortress
Cash FlowMixed
Top Statement Risk

Thin margins under reimbursement pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Demand Sustained Growth

Based on reported figures, GRDN trades at 42.3x trailing earnings and 25.2x EV/EBITDA, a premium that assumes growth durability even as year-over-year revenue growth decelerated to negative territory in the latest quarter.

The 42.3x trailing P/E and 2.25 PEG ratio indicate the market is pricing in earnings growth well above what the most recent quarter supports, since the Q3 2026 EPS miss against a $0.41 estimate weakens the near-term earnings base. Compared with the diversified distributor peers referenced in the peer set, the multiple is elevated, which suggests investors are paying a complexity premium for the long-term care service model rather than a pure distribution valuation. Investors should monitor whether forward EV/EBITDA compression toward 22.4x reflects genuine earnings recovery or simply a lower price base.

Thin Margins Limit Earnings Cushion

According to reported quarterly figures, GRDN's gross margin held near 23.0% in Q3 2026 while operating margin of 6.8% and net margin of 5.0% leave a narrow buffer against reimbursement cuts.

Gross margin has stayed in a narrow 19.4% to 23.0% band over the ten quarters shown, which suggests pricing power is limited and the business remains tethered to drug distribution economics. The gap between the 6.8% operating margin and 5.0% net margin, combined with 26.8% ROE, implies that returns are being generated more by balance sheet structure than by unusually strong operating profitability. Operating margin volatility between 3.7% and 9.2% suggests operating leverage is uneven and warrants monitoring of SG&A discipline as revenue scales.

Equity Returns Diverge From Invested Capital

As reported in financial statements, GRDN's ROIC of 9.4% in Q3 2026 sits well below its 26.8% ROE, pointing to returns that are heavily amplified by a thin equity base relative to operating earnings.

The spread between ROE and ROIC is a signal that much of the reported equity return reflects financial structure rather than deep capital efficiency, since the company carries minimal debt yet still shows modest invested-capital returns. ROIC has trended in a 5% to 14% range across recent quarters, which suggests compounding is real but inconsistent. Investors should track whether ROIC expands as goodwill from acquisitions, which rose from $66.4M to $82.0M, is absorbed into earnings.

Cash Build Strengthens Near-Term Coverage

Based on GRDN's reported balance sheet, the current ratio improved from 1.05 to 1.65 and quick ratio reached 1.33, indicating a materially larger liquidity buffer than in late 2024.

The improvement in quick ratio to 1.33 suggests the company can meet short-term obligations without relying on inventory liquidation, which is meaningful for a pharmacy distributor holding dispensing stock. However, the cash build coincides with thin earnings margins, so the liquidity position may be more dependent on working capital timing than on sustained profit generation. Under severe stress, the position would likely depend on whether receivables collect on schedule given DSO near 26 days.

Misapplied Metric Obscures Working Capital Reality

The debt-to-equity ratio is most commonly misapplied to GRDN, as its 0.13 reading may understate financial risk when cash conversion swings sharply quarter to quarter.

Low D/E is often read as a clean signal of balance sheet safety, but for a business whose operating cash flow relative to net income swung from 0.46x to 2.87x, the more informative measure is cash conversion and working capital intensity. Substituting a free cash flow margin trend or CCC analysis alongside D/E would better reflect the operating reality. Investors should weigh the Q1 2026 working capital outflow as a reminder that a low-leverage ratio does not guarantee stable cash generation.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open GRDN Terminal

GRDN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GRDN — Frequently Asked Questions

Quick answers to the most common questions about buying GRDN stock.

What is Guardian Pharmacy Services, Inc.'s P/E ratio?

Guardian Pharmacy Services, Inc.'s current P/E ratio is 40.1x. The historical average is 38.6x. This places it at the 100th percentile of its historical range.

What is Guardian Pharmacy Services, Inc.'s EV/EBITDA?

Guardian Pharmacy Services, Inc.'s current EV/EBITDA is 23.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.9x.

What is Guardian Pharmacy Services, Inc.'s ROE?

Guardian Pharmacy Services, Inc.'s return on equity (ROE) is 26.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 21.2%.

Is GRDN stock overvalued?

Based on historical data, Guardian Pharmacy Services, Inc. is trading at a P/E of 40.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Guardian Pharmacy Services, Inc.'s profit margins?

Guardian Pharmacy Services, Inc. has 19.5% gross margin and 6.1% operating margin.

How much debt does Guardian Pharmacy Services, Inc. have?

Guardian Pharmacy Services, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.